Evidence map›Paper›PMID 24097975›Full record

ArticleThe Journal of biological chemistry2013

Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.

Rustem I Litvinov, Serge V Yarovoi, Lubica Rauova, Valeri Barsegov, Bruce S Sachais, Ann H Rux, Jillian L Hinds, Gowthami M Arepally, Douglas B Cines, John W Weisel

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Cloning of Antibodies from Patients with Heparin-Induced Thrombocytopenia.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Rustem I LitvinovFrom the Department of Cell and Developmental Biology and.
Serge V Yarovoi
Lubica Rauova
Valeri Barsegov
Bruce S Sachais
Ann H Rux
Jillian L Hinds
Gowthami M Arepally
Douglas B Cines
John W Weisel
University of Pennsylvania · USChildren's Hospital of Philadelphia · USDuke University · USUniversity of Massachusetts Lowell · US

Funding

Protein CoreP01HL110860 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI RAUOVA, LUBICA · 2012 to 2016
$11.4M
Etiologic and therapeutic studies of heparin-induced thrombocytopenia (HIT)R01HL084006 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI PONCZ, MORTIMER · 2007 to 2011
$2.3M
Proatherogenic properties of platelet fator 4R01HL078726 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI SACHAIS, BRUCE S · 2006 to 2010
$2.1M
Structural origin of fibrin clot mechanical propertiesR01HL090774 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI WEISEL, JOHN W · 2009 to 2012
$1.6M
Novel Biomarkers Predictive of Heparin-Induced ThrombocytopeniaRC1HL099973 · NHLBI · BLOODWORKS · PI KONKLE, BARBARA A · 2009 to 2010
$997k
Structural origin of fibrin clot mechanical propertiesR56HL090774 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI WEISEL, JOHN W · 2014 to 2014
$408k
NHLBI NIH HHS HL078726/HL078726-S1NHLBI NIH HHS HL084006NHLBI NIH HHS HL099973/HL090774NHLBI NIH HHS HL110860NHLBI NIH HHS P01 HL110860NHLBI NIH HHS R01 HL078726NHLBI NIH HHS R01 HL084006NHLBI NIH HHS R01 HL090774NHLBI NIH HHS R56 HL090774NHLBI NIH HHS RC1 HL099973
6 · The paper itself

Abstract

Heparin-induced thrombocytopenia (HIT) is a thrombotic complication of heparin therapy mediated by antibodies to complexes between platelet factor 4 (PF4) and heparin or cellular glycosaminoglycans. However, only a fraction of patients with anti-PF4-heparin antibodies develop HIT, implying that only a subset of these antibodies is pathogenic. The basis for the pathogenic potential of anti-PF4-heparin antibodies remains unclear. To elucidate the intrinsic PF4-binding properties of HIT-like monoclonal antibody (KKO) versus non-pathogenic antibody (RTO) at the single-molecule level, we utilized optical trap-based force spectroscopy to measure the strength and probability of binding of surface-attached antibodies with oligomeric PF4 to simulate interactions on cells. To mimic the effect of heparin in bringing PF4 complexes into proximity, we chemically cross-linked PF4 tetramers using glutaraldehyde. Analysis of the force histograms revealed that KKO-PF4 interactions had ∼10-fold faster on-rates than RTO-PF4, and apparent equilibrium dissociation constants differed ∼10-fold with similar force-free off-rates (k(off) = 0.0031 and 0.0029 s(-1)). Qualitatively similar results were obtained for KKO and RTO interacting with PF4-heparin complexes. In contrast to WT PF4, KKO and RTO showed lower and similar binding probabilities to cross-linked PF4(K50E), which forms few if any oligomers. Thus, formation of stable PF4 polymers results in much stronger interactions with the pathogenic antibody without a significant effect on the binding of the non-pathogenic antibody. These results suggest a fundamental difference in the antigen-binding mechanisms between model pathogenic and non-pathogenic anti-PF4 antibodies that might underlie their distinct pathophysiological behaviors.

Indexed as

Antibody SpecificityAntibodies, MonoclonalAnticoagulantsAutoantibodiesBinding Sites, AntibodyHeparinHumansKineticsPlatelet Factor 4ThrombocytopeniaAntibodies, MonoclonalAnticoagulantsAutoantibodiesHeparinPlatelet Factor 4AntibodiesHeparin-binding ProteinPlateletsSingle Molecule BiophysicsThrombosis

Identifiers

PMID24097975
PMCPMC3829155
OpenAlexW2170630405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.